ReviewPharmaceutical research2023
Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.
Review in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- The Impact of Surfactants in Tailoring Nanostructured Lipid Carriers for Inhaled Levofloxacin.ACS omega · 2026Article
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Inhaled Antibiotic and Biologic Formulations TargetingPharmaceutics · 2026Review
- Inhalable Nanosystems for Bacterial Respiratory Infections: Addressing Pulmonary Barriers and Biofilm-Associated Challenges.International journal of nanomedicine · 2026Review
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Evaluation of Combinatorial Efficacy of Nisin and Lactoferrin against Pseudomonas Aeruginosa Induced Experimental Pulmonary Infection Model.Current microbiology · 2025Article
- New Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.Probiotics and antimicrobial proteins · 2025Review
- From Microbial Ecology to Clinical Challenges: The Respiratory Microbiome's Role in Antibiotic Resistance.Pathogens (Basel, Switzerland) · 2025Review
- Pneumonia: Recent Updates on Diagnosis and Treatment.Microorganisms · 2025Review
- Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.Pharmaceutics · 2024Review
- Evaluating the effect of sodium alginate and sodium carboxymethylcellulose on pulmonary delivery of levofloxacin spray-dried microparticles.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation.Pharmaceutics · 2024Article
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Review
- Advances in Pulmonary Drug Delivery Systems and Inhalation Formulations.Pharmaceutical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial infections in the respiratory tract are considered as one of the major challenges to the public health worldwide. Pulmonary delivery is an attractive approach in the management of bacterial respiratory infections with a few inhaled antibiotics approved. However, with the rapid emergence of antibiotic-resistant bacteria, it is necessary to develop new/alternative inhaled antibacterial agents in the post-antibiotic era. A pipeline of novel biological antibacterial agents, including antimicrobial peptides, RNAi therapeutics, and bacteriophages, has emerged to combat bacterial infections with excellent performance. In this review, the causal effects of bacterial infections on the related pulmonary infectious diseases will be firstly introduced. This is followed by an overview on the development of emerging antibacterial therapeutics for managing lung bacterial infections through nebulization/inhalation of dried powders. The obstacles and underlying proposals regarding their clinical transformation are also discussed to seek insights for further development. Research on inhaled therapy of these emerging antibacterials are still in the infancy, but the promising progress warrants further attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.